Skip to content

Study · Non-randomized trial · n = 22 · 1978

6 results

Desmopressin in the management of nocturnal enuresis in children: a double-blind study.

Birkásová M, Birkás O, Flynn MJ, Cort JH

Pediatrics1 Dec 1978Cited by 51 (Europe PMC)

PMID366538 (opens in a new tab)DOI10.1542/peds.62.6.970 (opens in a new tab)PepBankPUB-00366538
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with persistent enuresis, desmopressin reduced wetting frequency to 4.2 ± 4.5 nights per fortnight versus placebo.

    In plain wordsIn children with persistent bedwetting, desmopressin reduced wet nights compared with saline placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseWetting frequency versus placebo
    Study

    n = 22

    Comparator
    Saline placebo
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · nose drops · fortnightAs given in this study (human).

    Measurements

    Wetting frequency
    10.6 nights per fortnight
    pretreatment
    Wetting frequency
    11 nights per fortnight
    placebo
    Wetting frequency
    4.2 nights per fortnight
    desmopressin

    Source sentences

    Summary
    The value of the fortnight during desmopressin therapy was 4.2 +/- 4.5, which was significantly different from either of the previous means (P less than .01).
    3 context sentences
    Summary · context
    Pretreatment and placebo fortnights showed wetting frequencies (nights per fortnight) of 10.6 +/- 4.9 and 11.0 +/- 4.4, respectively.
    Summary · context
    Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 +/- 2.9 years; range, 4 to 12 years) the evening before sleep.
    Summary · context
    With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with persistent enuresis, desmopressin reduced wetting frequency to 4.2 ± 4.5 nights per fortnight versus pretreatment.

    In plain wordsIn children with persistent bedwetting, desmopressin reduced wet nights compared with before treatment.

    Peptide
    Desmopressin
    Outcome
    DecreaseWetting frequency versus pretreatment
    Study

    n = 22

    Comparator
    Pretreatment
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · nose drops · fortnightAs given in this study (human).

    Measurements

    Wetting frequency
    10.6 nights per fortnight
    pretreatment
    Wetting frequency
    11 nights per fortnight
    placebo
    Wetting frequency
    4.2 nights per fortnight
    desmopressin

    Source sentences

    Summary
    The value of the fortnight during desmopressin therapy was 4.2 +/- 4.5, which was significantly different from either of the previous means (P less than .01).
    3 context sentences
    Summary · context
    Pretreatment and placebo fortnights showed wetting frequencies (nights per fortnight) of 10.6 +/- 4.9 and 11.0 +/- 4.4, respectively.
    Summary · context
    Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 +/- 2.9 years; range, 4 to 12 years) the evening before sleep.
    Summary · context
    With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home.
  3. 03HumanNon-randomized trialEfficacy outcome

    Four of 22 children did not respond to desmopressin therapy.

    In plain wordsFour of 22 children did not respond to desmopressin therapy.

    Peptide
    Desmopressin
    Outcome
    Not applicableFailure to respond
    Study

    n = 22

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · nose dropsAs given in this study (human).

    Measurements

    Children who failed to react to therapy
    4 children
    of 22 children given desmopressin

    Source sentences

    Summary
    Of the 22 subjects, four failed to react to therapy at all.
    2 context sentences
    Summary · context
    Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 +/- 2.9 years; range, 4 to 12 years) the evening before sleep.
    Summary · context
    With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home.
  4. 04HumanNon-randomized trialEfficacy outcome

    During desmopressin therapy, enuretic frequency decreased in the remaining 18 children.

    In plain wordsDuring desmopressin therapy, bedwetting decreased in the remaining 18 children.

    Peptide
    Desmopressin
    Outcome
    DecreaseDecreased enuretic frequency
    Study

    n = 22

    Comparator
    Pretreatment
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · nose dropsAs given in this study (human).

    Measurements

    Children with decreased enuretic frequency
    18 children
    remaining children after four non-reactors, of 22

    Source sentences

    Summary
    There was decreased enuretic frequency in the remaining 18, of whom 12 decreased markedly or ceased wetting.
    2 context sentences
    Summary · context
    Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 +/- 2.9 years; range, 4 to 12 years) the evening before sleep.
    Summary · context
    With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home.
  5. 05HumanNon-randomized trialEfficacy outcome

    Among 18 responding children, 12 markedly reduced or stopped wetting during desmopressin therapy.

    In plain wordsAmong 18 responding children, 12 markedly reduced or stopped bedwetting during desmopressin therapy.

    Peptide
    Desmopressin
    Outcome
    DecreaseMarked reduction or cessation
    Study

    n = 18

    Comparator
    Pretreatment
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · nose dropsAs given in this study (human).

    Measurements

    Children who decreased markedly or ceased wetting
    12 children
    of the 18 children with decreased frequency

    Source sentences

    Summary
    There was decreased enuretic frequency in the remaining 18, of whom 12 decreased markedly or ceased wetting.
    2 context sentences
    Summary · context
    Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 +/- 2.9 years; range, 4 to 12 years) the evening before sleep.
    Summary · context
    With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home.
  6. 06HumanNon-randomized trialEfficacy outcome

    One month after the trial, seven respondents were dry with desmopressin therapy.

    In plain wordsOne month after the trial, seven responding children were dry with desmopressin therapy.

    Peptide
    Desmopressin
    Outcome
    Not applicableDryness one month after trial
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · nose dropsAs given in this study (human).

    Measurements

    Respondents dry with desmopressin
    7 children
    one month after the trial

    Source sentences

    Summary
    One month after the trial, seven of the respondents were dry with desmopressin therapy.
    2 context sentences
    Summary · context
    Desmopressin (1-desamino-[8-D-Arg]-vasopressin) (DDAVP) was given by nose drops to 22 children with persistent nocturnal enuresis (mean age, 6.6 +/- 2.9 years; range, 4 to 12 years) the evening before sleep.
    Summary · context
    With saline alone as placebo and with comparison to enuretic frequency before the onset of the trial, fortnightly periods were compared under double-blind conditions with the children at home.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.